Y-mAbs Therapeutics, Inc.
YMAB
$5.11
$0.030.59%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 21.62% | -587.25% | 9.67% | -46.76% | -3.74% |
Total Depreciation and Amortization | -55.35% | -36.65% | -27.98% | -31.70% | -12.64% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -41.70% | 170.58% | 7.10% | 11.31% | -10.52% |
Change in Net Operating Assets | -220.82% | 87.04% | -298.57% | 392.89% | 88.57% |
Cash from Operations | -98.76% | 76.73% | -697.09% | 106.29% | 73.51% |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | -- | -- | -- | -- |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -80.61% | 886.00% | -- | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -80.61% | 886.00% | -- | -- | -- |
Foreign Exchange rate Adjustments | -- | -300.00% | -- | -92.86% | 111.11% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -139.75% | 88.81% | -623.77% | 143.58% | 78.01% |